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Background: Eicosanoids derived from omega-6 (n6) polyunsaturated fatty acids (PUFAs) have proinflammatory
functions whereas eicosanoids derived from omega-3 (n3) PUFAs have anti-inflammatory properties. This study was
designed to evaluate the effect of insulin analog initiation therapy on n6 and n3 PUFAs in type 2 diabetic patients
during early phase.
Methods: Sixteen type 2 diabetic patients with glycosylated hemoglobin (HbA1c) levels above 10% despite
ongoing combination therapy with sulphonylurea and metformin were selected. Former treatment regimen was
continued for the first day followed by substitution of sulphonylurea therapy with different insulin analogs
(0.4 U/kg/day) plus metformin. Blood samples were obtained from all patients at 24 and 72 hours. Plasma levels
of arachidonic acid (AA, C20:4n6), dihomo-gamma-linolenic acid (DGLA, C20:3n6), eicosapentaenoic acid
(EPA, C20:5n3) and docosahexaenoic acid (DHA, C22:6n3) were determined by an optimized multiple reaction
monitoring (MRM) method using ultra fast-liquid chromatography (UFLC) coupled with tandem mass spectrometry
(MS/MS). Prostaglandin E2 (PGE2) was measured in serum samples by enzyme immunoassay.
Results: All measured PUFAs were significantly increased after treatment with insulin analogs plus metformin
compared to before treatment levels. The mean AA/EPA ratio was significantly lower after treatment with insulin
analogs plus metformin. A 22% decrease was observed in PGE2 levels after treatment with insulin analogs plus
metformin compared to pretreatment levels (p > 0.05).
Conclusion: The significant decrease in AA/EPA ratio indicates that insulin analog initiation therapy has
anti-inflammatory properties by favoring the increase of n3 fatty acid EPA.
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Increasing evidence supports the role of chronic inflamma-
tion in the pathogenesis of diabetes-associated microvas-
cular and macrovascular complications [1]. Inflammatory
cytokines, such as interleukin- 6 (IL-6), IL-1, and IL-18, as
well as tumor necrosis factor- alpha (TNF-α), are involved
in the development and progression of diabetic complica-
tions [2]. Preliminary results from clinical trials with salicy-
lates and interleukin-1 antagonists support the hypothesis
that the pathogenesis of type 2 diabetes mellitus (T2DM)* Correspondence: mutayaslan@akdeniz.edu.tr
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stated.reflects an inflammatory disorder [3]. Anti-inflammatory
therapeutics simultaneously lower blood glucose levels,
reduce the severity and prevalence of associated diabetic
complications [4].
Polyunsaturated fatty acids (PUFAs) regulate inflam-
matory responses through the production of eicosanoids
including prostaglandins (PGs), thromboxanes (TXs)
and leukotrienes (LTs) [5]. The human body can produce
many fatty acids except the two essential PUFAs which
include linoleic acid (LA, C18:2n6) and alpha-linolenic
acid (ALA, C18:3n3). Linoleic acid is the precursor of
omega-6 (n6) series of PUFAs while ALA is the pre-
cursor of omega-3 (n3) series of PUFAs. Eicosanoids
derived from n6 PUFAs such as arachidonic acidtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited. The Creative Commons Public Domain Dedication
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Table 1 Patient characteristics and laboratory values
Variable Mean ± SD n
Age (years) 54.88 ± 11.76 16
BMI (kg/m2) 25.22 ± 2.15 16
HbA1c (%) 11.79 ± 2.41 16
BUN (mg/dl) 12.56 ± 3.05 16
Serum Creatinine (mg/dl) 0.81 ± 0.17 16
Microalbumin (mg/24h) 26.69 ± 18.57 16
ALT (U/L) 20.75 ± 10.60 16
AST (U/L) 24.00 ± 10.40 16
TSH (μU/L) 1.13 ± 0.64 16
BMI, body mass index; HbA1c, hemoglobin A1c; BUN, blood urea nitrogen;
ALT, alanine aminotransferase; AST, aspartate aminotransferase; TSH, thyroid
stimulating hormone.
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tive functions, whereas eicosanoids derived from n3
PUFAs such as eicosapentaenoic acid (EPA, C20:5n3)
have anti-inflammatory properties, attributed to their
ability to inhibit the formation of n6 PUFA-derived
eicosanoids [5]. Resolvins and protectins generated
from EPA and docosahexaenoic acid (DHA, C22:6n3)
display potent anti-inflammatory properties and are
recognized in the resolution of inflammation [6].
The beneficial effects of n3 PUFA, has been shown in
obese-diabetic mice [7]. Omega-3 PUFA enriched diet
increased expression of genes involved in glucose trans-
port [glucose transporter type 4 (GLUT-4)] and insulin
signaling [insulin receptor substrate 1 (IRS-1)], as well
as genes involved in insulin sensitivity [peroxisome
proliferator-activated receptor gamma (PPARγ)] [7].
There is also evidence showing that use of n3 PUFA
supplementation improves clinical outcomes of patients
with diabetes. In a diabetic and insulin-resistant state, n3
PUFAs bind to the G-protein coupled receptor 120
(GPR120), resulting in reduced cytokine production from
inflammatory macrophages and improved signaling in
adipocytes, leading to a reduction in insulin resistance [8].
Insulin stimulates the conversion of essential fatty
acids (LA and ALA) to longer-chain PUFAs [9]. Indeed,
levels of the principal n6 PUFA, AA, are reported to be
significantly lower in diabetic patients than in controls
[10,11]. Moreover, the contents of n3 PUFAs are decrea-
sed in serum and platelet lipids of diabetic patients
compared to healthy controls [12]. It was hypothesized
herein that insulin analog initiation therapy may increase
long chain PUFAs and change AA/EPA ratio which is a
marker of silent inflammation. Thus, this study was
designed to evaluate the effect of insulin analog initi-
ation therapy on n6 and n3 PUFAs in type 2 diabetic
patients during early phase.
Materials and methods
Patients
The study group included 16 patients who were admitted
to Antalya Research and Education Hospital, Endocrin-
ology Clinic with a diagnosis of T2DM. Patient charac-
teristics and laboratory values are shown in Table 1. The
body mass index (BMI) of all patients enrolled in the
study was <30 kg/m2 and all were non-smokers. None of
the patients received antilipidemic agents in the last
3 months before the study. Subjects with apparent history
of stroke, coronary heart disease, peripheral artery disease,
severe kidney dysfunction, liver disease, thyroid dysfunc-
tion, infectious disease, and malignancy were excluded.
All subjects enrolled were maintained on a standardized
diet before the initiation of the study. HbA1c levels in all
patients were above 10% despite ongoing therapy with
sulphonylurea and metformin for at least 3 months.Former treatment regimen was continued for the first day
followed by substitution of sulphonylurea therapy with
insulin analogs. Patients received either 0.4 U/kg/day
lispro mix (50% insulin lispro protamine and 50% insulin
lispro) subcutaneously (SC) in three equal doses plus
2000 mg/day oral metformin; or 0.4 U/kg/day insulin
glargine SC in one dose plus 2000 mg/day oral metformin.
The given insulin treatments were in accordance with
American Association of Clinical Endocrinologists (AACE)
Diabetes Mellitus guidelines [13]. All patients gave written
informed consent prior to entry. This study was approved
by the Institutional Review Board of Antalya Research and
Education Hospital and was performed in accordance with
the Declaration of Helsinki.
Laboratory measurements
Blood was obtained from all patients at 24 and 72 hours.
HbA1c levels were determined by Abbott ARCHITECT
c16000 System (Abbott Diagnostic, Abbott Park Illinois,
USA) via immunoturbidimetric method. Total cholesterol
(TC), HDL-C and triacylglycerol (TG) were measured on
Roche Cobas 8000 Modular Analyser (Basel, Switzerland)
via enzymatic colorimetric methods. Low-density lipo-
protein cholesterol (LDL-C) and very low-density lipopro-
tein cholesterol (VLDL-C) levels were calculated via the
Friedewald formula [14]. Blood urea nitrogen (BUN),
serum creatinine, alanine aminotransferase (ALT), and
aspartate aminotransferase (AST) were measured on Roche
Cobas 8000 Modular Analyzer via colorimetric methods.
Serum thyroid stimulating hormone (TSH) and urine
microalbumin was measured on Roche Cobas 8000 Mo-
dular Analyzer via electrochemiluminescence immunoassay
and turbidimetric methods, respectively.
Electrospray ionization mass spectrometry
Standards for AA (C20:4n6), DGLA (C20:3n6), EPA
(C20:5n3) and DHA (C22:6n3) were purchased from
Sigma-Aldrich (St. Louis MO, USA). Deuterium labeled
AA-d8 internal standard (5,6,8,9,11,12,14,15-AA-d8) was
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CA, USA). Solutions of AA, DGLA, EPA, DHA and AA-
d8 standards were prepared in analytical grade methanol
(Merck, Darmstadt, Germany). An optimized multiple
reaction monitoring (MRM) method was developed
using ultra-fast liquid chromatography (UFLC) coupled
with tandem mass spectrometry (MS/MS). A UFLC
system (LC-20 AD UFLC XR, Shimadzu Corporation,
Japan) was coupled to a LCMS-8040 triple quadrupole
mass spectrometer (Shimadzu Corporation, Japan). Chro-
matographic separations were carried out using Inertsil
HPLC column (ODS-4, 2.1×100 mm, 3 μm; GL Sciences
Inc. Tokyo, Japan) maintained at 40°C. DHA, EPA, AA
and DGLA were separated using a gradient elution with a
flow rate of 0.45 ml/min. Mobile phase solvent A was
10 mM ammonium acetate (Sigma-Aldrich, St. Louis,
MO, USA) in water and solvent B was acetonitrile (Sigma-
Aldrich, St. Louis, MO, USA). Gradient program was
solvent B, 70% (0 min), 90% (3 min), 100% (3.01-4 min)
and 70% (4.01-8 min). MRM transitions and responses
were automatically optimized for individual compounds in
negative electrospray ionization (ESI). In the negative ESI-
MS mode the precursor and product m/z values for AA,
DHA, EPA, DGLA and AA-d8 are given in Table 2.
Responses to AA, DHA, EPA and DGLA were optimized
to a linear calibration range from 100 ng/ml to 30 ug/ml
and a sample analysis time of 8 minutes.
Sample preparation for LC-MS/MS
Samples were prepared for LC-MS/MS analysis via a
modified protocol as previously described [15]. Briefly,
in a glass test tube, 200 μl plasma was added to 200 μl
AA-d8 internal standard solution. 1 ml of acetonitril/
37% hydrochloric acid (Cayman, Ann Arbor, MI, USA)
was added to the mixture in a 4:1 v/v. Tubes were
capped with reusable teflon liner screw caps and samples
were hydrolyzed by incubating at 90°C for 2 hours in a
heating block (VLM, Bielefeld, Germany). After cooling
down to room temperature, fatty acids were extracted
with 2 ml of hexane. Samples were vortex-mixed for
20 seconds, left at room temperature for 5 minutes and
centrifuged at 3000 rpm for 1 minute. The upper phase
containing free fatty acids were transferred to glass tubesTable 2 The precursor and product m/z values for
analyzed polyunsaturated fatty acids
Precursor m/z Product m/z
DGLA (C20:3n6) 304.80 59.00, 260.70
AA (C20:4n6) 303.10 59.00, 258.90
EPA (C20:5n3) 301.10 59.10, 256.70
DHA (C22:6n3) 327.10 59.10, 283.20
AA-d8 311.10 59.10, 97.90, 267.10
DGLA, dihomo-gamma-linolenic acid; AA, arachidonic acid; EPA, eicosapenta-
enoic acid; DHA, docosahexaenoic acid.and evaporated at room temperature under a constant
stream of nitrogen with height adjustable gas distribution
unit (VLM, Bielefeld, Germany). Fatty acids were dissolved
in 200 μl methanol–water (180:20, v/v) filtered via 0,2 μm
polytetrafluoroethylene (PTFE) syringe filters (Whatman,
GE Healthcare Bio-Sciences, Pittsburgh, USA) and trans-
ferred to autosampler vials (Vertical Chromatography,
Nonthaburi, Thailand).
Measurement of prostaglandin E2
Prostaglandin E2 (PGE2) was measured in serum sam-
ples by a commercial enzyme immunoassay test kit
[KGE004B; R&D Systems, Inc., Minneapolis, MN 55413,
USA] according to manufacturer’s instructions. Briefly,
PGE2 present in the sample competes with horseradish
peroxidase (HRP)-labeled PGE2 for binding sites on a
mouse monoclonal antibody. PGE2 in the sample is
allowed to bind to the antibody in the first incubation.
During the second incubation, HRP-labeled PGE2 binds
to the remaining antibody sites. Following a wash to
remove unbound materials, a substrate solution is added
to the wells to determine the bound enzyme activity.
The color development is stopped, and the absorbance
is read at 450 nm. The intensity of the color is inversely
proportional to the concentration of PGE2 in the sam-
ple. A standard curve of absorbance values of known
PGE2 standards was plotted as a function of the loga-
rithm of PGE2 standard concentrations (pg/ml) using
the GraphPad Prism Software program for windows
version 5,03. (GraphPad Software Inc). PGE2 concentra-
tions in the samples were calculated from their corres-
ponding absorbance values via the standard curve.
Statistical analysis
Data were analyzed using Sigma Stat (version 2.03)
statistical software for Windows, and a P value < 0.05 was
considered statistically significant.
Results
Blood glucose and lipid profile
Mean blood glucose, TG and VLDL-C levels were signifi-
cantly decreased while HDL-C levels were significantly
increased after treatment with insulin analogs plus metfor-
min compared to before treatment levels (Table 3). No
significant decrease was observed in TC and LDL-C levels
after treatment with insulin analogs plus metformin.
Statistical analysis was done by paired t-test. The observed
decrease in TG concentration and the increase in HDL-C
support previous observations on the effect of insulin on
plasma lipid levels [16].
ESI-MS spectra
Figure 1A shows representative negative ion mode spec-
tra of a patient sample. As shown in the figure, retention
Table 3 Mean blood glucose and lipid profile before and after insulin analog initiation therapy
Parameter Before treatment (mean ± SD) After treatment (mean ± SD) n p value
Glucose (mg/dl) 229.31 ± 49.78 183.00 ± 57.25* 16 <0.001
Total cholesterol (mg/dl) 219.50 ± 42.97 207.81 ± 39.56 16 0.056
TG (mg/dl) 225.73 ± 68.42 191.40 ± 71.08* 15 0.025
VLDL-C (mg/dl) 45.15 ± 13.68 38.28 ± 14.22* 15 0.025
LDL-C (mg/dl) 141.52 ± 39.99 134.25 ± 39.01 15 0.175
HDL-C (mg/dl) 32.25 ± 8.16 35.31 ± 9.29* 16 0.006
TG, triglyceride; VLDL-C, very low-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; HDL-C, high-density lipoprotein cholesterol.*, p < 0.05.









































Figure 1 ESI-MS Spectra. A) Representative negative ion mode spectra of a patient sample. DGLA, Dihomo-gamma-linolenic acid; AA, Arachidonic
acid; EPA, Eicosapentaenoic acid; DHA, Docosahexaenoic acid. B) Tandem mass spectra.
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AA-d8 and DGLA (C20:3n6) was 1.869, 2.131, 2.391,
2.329 and 2.911 minutes. Figure 1B shows tandem mass
spectra obtained by collision-induced dissociation of
precursor ions. The m/z values of product ions corres-
pond to endogenous C20:5n3, C20:4n6, C20:3n6 and
C22:6n3. The deuterium-labeled internal standard fatty
acid peaks are indicated at m/z values 97.9 and 267.1.
Levels of polyunsaturated fatty acids
Levels of PUFAs before and after insulin analog therapy
are given in Table 4. All measured PUFAs were signifi-
cantly increased after treatment with insulin analogs plus
metformin compared to before treatment levels. The
mean AA/EPA ratio was significantly lower after treat-
ment with insulin analogs plus metformin. No signifi-
cant decrease was observed in AA/DHA ratio after
treatment with insulin analogs plus metformin (Table 4).
Statistical analysis was done by paired t-test. Compa-
rison of AA (C20:4n6), DGLA (C20:3n6), EPA (C20:5n3)
and DHA (C22:6n3) in serum samples before and after
insulin analog therapy are shown in Figure 2.
Prostaglandin E2 Levels
Box plot graph data of serum PGE2 content are shown
in Figure 3. The boundary of the box closest to zero in-
dicates the 25th percentile, the line within the box marks
the median, and the boundary of the box farthest from
zero indicates the 75th percentile. Whiskers above and
below the box indicate the 90th and 10th percentiles.
Approximately 22% decrease was observed in PGE2
levels after treatment with insulin analogs plus metfor-
min (p > 0.05). PGE2 (mean ± SEM) measured after
treatment with insulin analogs (477.17 ± 66.58 pg/ml)
was decreased compared to before treatment level
(613.39 ± 63.79 pg/ml). Statistical analysis was done by
paired t-test.
Discussion
Altered availability of long chain PUFAs has been linked
to the development of vascular complications and to the
impairment of peripheral nerve function of diabetic pa-
tients [17]. We have seen that insulin analog initiationTable 4 Analysis of polyunsaturated fatty acids before and af
Parameter Before treatment (mean ± SD)
DGLA (C20:3n6) (μg/ml) 44.11 ± 13.97
AA (C20:4n6) (μg/ml) 100.10 ± 23.28
EPA (C20:5n3) (μg/ml) 3.98 ± 3.09
DHA (C22:6n3) (μg/ml) 31.33 ± 13.31
AA/DHA 3.47 ± 1.08
AA/EPA 31.28 ± 11.76
DGLA, Dihomo-gamma-linolenic acid; AA, Arachidonic acid; EPA, Eicosapentaenoic atherapy plus metformin significantly increased plasma
levels of AA (C20:4n6), DGLA (C20:3n6), EPA (C20:5n3)
and DHA (C22:6n3) compared to before treatment levels.
As far as we know, no report has addressed the effect of
insulin analog initiation therapy on plasma PUFA levels in
patients with T2DM.
Fatty acid composition of serum phospholipids were
measured in 11 type 1 diabetic patients after a day of
hyperglycemia and after normoglycemia was reestablished
by insulin infusion. An increase was observed in AA,
DGLA, EPA and DHA content of serum phospholipids
after normoglycemia was reestablished as compared to
hyperglycemic levels [18]. Similarly, plasma fatty acid
composition was reported in 9 type 1 diabetic children
during and after diabetic ketoacidosis (DKA) and an in-
crease was observed in AA and DHA values after treat-
ment of DKA [19].
Disturbed fatty acid metabolism is an important
feature of the insulin-resistant state [20]. Essential fatty
acids are metabolized into more physiologically active
compounds by introduction of further double bonds by
delta-5- and delta-6-desaturase enzymes [9]. The hepatic
microsomal delta-6-desaturation of LA and ALA was
found to be depressed in alloxan induced diabetic rats
[21]. The observed enzymatic defect was corrected by
insulin injection in 2 days [22]. It was demonstrated that
blocking mRNA transcription by actinomycin D injec-
tion before insulin administration impaired the recovery
of delta-6 desaturase activity suggesting that insulin
induced the synthesis of delta-6 desaturase. Indeed it was
later shown that delta-6- desaturase mRNA was 7 fold
lower in streptozotocin-diabetic rat than in the control
and the administration of insulin induced the enzyme
mRNA 8 fold within 24 hours [23]. In vivo experiments
also showed similar effects of diabetes on rat liver delta-5
desaturation and the correcting effect of insulin [24].
Animal studies investigating the role of type 2 diabetes on
fatty acid desaturases are limited and not very clear. How-
ever reported data herein demonstrate for the first time
that insulin analog initiation therapy in T2DM patients
does increase long chain PUFAs in human plasma.
Another important finding of the presented work is
that treatment with insulin analogs plus metforminter insulin analog initiation therapy
After treatment (mean ± SD) n p value
60.84 ± 10.72* 16 <0.001
117.65 ± 24.66* 16 0.018
5.07 ± 2.25* 16 0.004
38.16 ± 11.66 * 16 <0.001
3.23 ± 0.77 16 0.065
25.34 ± 7.88* 16 0.006



















































































Figure 2 Levels of polyunsaturated fatty acids in patients before and after insulin analog therapy. A) AA B) DGLA C) EPA D) DHA. DGLA,
Dihomo-gamma-linolenic acid; AA, Arachidonic acid; EPA, Eicosapentaenoic acid; DHA, Docosahexaenoic acid.
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pared to pretreatment levels. Competition between n6
and n3 fatty acids occurs in the production of eicosa-
noids by stereospecific lipid-oxidizing enzymes cylooxy-
genase (COX) and lipoxygenase (LOX) [25]. Eicosanoids,
derived mainly from AA and EPA, are key mediators and
regulators of inflammation. They include PGs, TXs, LTs
and hydroxyeicosatetraenoic acids (HETEs) [26]. Eicosa-

















Figure 3 Prostaglandin E2 Levels before and after insulin
analog therapy.with less marked inflammatory effect. On the other hand,
AA is a precursor of eicosanoids with definite inflam-
matory effect [27]. Hence, decreased AA to EPA ratio
indicates less precursor for the synthesis of highly inflam-
matory eicosanoids.
Production of PGs occur by stereospecific lipid-oxidiz-
ing enzymes. Experimental animal models of diabetes
have shown that PG synthesis is active in the presence
of insulin deficiency [28] and that plasma and urine lipid
oxidation are markedly decreased following insulin ana-
log plus metformin treatment [29]. AA is a precursor of
PGE2 synthesis and thus, decreased PGE2 levels follow-
ing treatment with insulin analogs may also play a role
in the observed increase of arachidonic acid.
Limitations of our study include (1) the study covers a
small cohort 2) the study has not determined LA and
ALA levels. Determining LA and ALA levels in patients
enrolled in the study might have strengthened analysis
of the data. Higher concentrations of LA result in a
greater conversion of LA to arachidonic acid [30]. Simi-
larly, increasing ALA intake results in significant enhan-
cement in the EPA content of plasma phospholipids
[31]. Decreasing LA in the diet to an optimal LA/ALA
ratio of 4:1 results in higher plasma phospholipid EPA
[32]. Around 8–20% of ALA is converted to EPA in
Aslan et al. Lipids in Health and Disease 2013, 12:169 Page 7 of 8
http://www.lipidworld.com/content/12/1/169humans, while conversion of ALA to DHA is less and
predicted to be around 0.5–9% [33].
In conclusion, we have observed that treatment with
insulin analog plus metformin resulted in a significant
increase in long chain PUFAs and a significant decrease in
AA/EPA ratio. These alterations may be of importance to
understand the role of insulin analog therapy in decreas-
ing the progression of chronic diabetic complications.
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